India-based Sun Pharma & Israel-based Moebius Medical Releases Articles on MM-II

Sun Pharmaceutical Industries and Moebius Medical, based in Israel, announced that two articles highlighting MM-II, a novel non-opioid product for the treatment of symptomatic knee osteoarthritis, were published in Osteoarthritis and Cartilage, the official journal of the Osteoarthritis Research Society International (OARSI).

The foundation of MM-II is a patented suspension of big, empty, multilamellar liposomes that are intended to lessen joint wear and friction and, consequently, pain. The two articles highlight the potential therapeutic utility of MM-II by providing complementary insights into its clinical efficacy and mechanism of action.

Results from a Phase 2b randomized, double-blind, placebo-controlled trial (NCT04506463), which included 397 patients from the US, Europe, and Asia, are presented in the first publication. Results show that a single MM-II injection had a good safety and tolerability profile and produced clinically significant pain reduction for 26 weeks.

The second article describes the special mode of action of MM-II and is titled Empty big liposomes decrease cartilage degradation in osteoarthritic rats by producing a lubricative covering. According to the study, MM-II lubricates cartilage surfaces, lowering friction and delaying cartilage deterioration. The coating of the cartilage surfaces may have mediated the clinical trial's results, according to the scientists, however other mechanisms might have contributed to the Phase 2b study's long-term pain reduction.

According to Prof. Thomas J. Schnitzer, MD, PhD, a rheumatologist and professor of medicine at Northwestern University and the primary author of the clinical trial report, the data from these publications demonstrate that MM-II has the potential to offer patients long-lasting pain relief.